Gilead Sciences | GILD - Capitale Ordinario





Capitale Ordinario Cambiamento Data
AbbVie USD 1.77B 1.75B 2025-06
Agios Pharmaceuticals USD 59.34M 892K 2026-03
ALKERMES USD 167.54M 1.08M 2026-06
Alnylam Pharmaceuticals USD 133.73M 290K 2026-06
Amgen USD 541M 1000K 2026-06
Biogen USD 146.7M 200K 2025-09
BioMarin Pharmaceutical USD 193.54M 267K 2026-06
Bristol-Myers Squibb USD 2.04B 1.74B 2025-09
Coherus Biosciences USD 121.16M 4.92M 2025-12
Eli Lilly USD 943.5M 3.33M 2026-03
Gilead Sciences USD 1.24B 1000K 2026-06
GlaxoSmithKline GBP 4.08B 20.6M 2026-06
Glaxosmithkline GBP 4.05B 20.6M 2026-03
Incyte USD 200.98M 1.03M 2026-06
J&J USD 2.41B 1.64M 2026-06
Merck USD 2.47B 4.93M 2026-03
Moderna USD 391M 2M 2025-09
Neurocrine Biosciences USD 100.55M 50K 2026-06
Novartis USD 1.9B 7.38M 2026-06
Pfizer USD 5.7B 0 2026-06
PTC Therapeutics USD 83.33M 445K 2026-06
Puma Biotechnology USD 5K 0 2024-06
Regeneron Pharmaceuticals USD 105M 300K 2026-03
Sanofi EUR 1.21B 8.25M 2026-03
Sarepta Therapeutics USD 105.62M 53K 2026-06
United Therapeutics USD 42.68M 521K 2026-06
Vertex Pharmaceuticals USD 253.3M 900K 2026-06